Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature

被引:389
作者
Baran, Burcin [1 ]
Ozupek, Nazli Mert [1 ]
Tetik, Nihal Yerli [1 ]
Acar, Emine [2 ,3 ]
Bekcioglu, Omer [1 ]
Baskin, Yasemin [1 ,4 ]
机构
[1] Dokuz Eylul Univ, Inst Oncol, Dept Basic Oncol, Izmir, Turkey
[2] Dokuz Eylul Univ, Dept Translat Oncol, Izmir, Turkey
[3] Katip Celebi Univ, Dept Nucl Med, Izmir, Turkey
[4] Dokuz Eylul Univ, Personalized Med & Pharmacogen Res Ctr, Izmir, Turkey
关键词
Colorectal cancer; Right side; Left side; Epidemiology; Molecular mechanism; Adjuvant chemotherapies; Targeted therapies; Immunotherapies;
D O I
10.14740/gr1062w
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Colorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages. However, colorectal cancer is not a single type of tumor; its pathogenesis depends on the anatomical location of the tumor and differs between right side and left side of the colon. Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology. Therapy responses are totally different between these tumor entities. Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti-epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load. For the development of effective therapy regimes and better treatment options, it is essential to evaluate right-sided and left-sided tumors as separate entities, and design the therapy regime considering the differences between these tumors.
引用
收藏
页码:264 / 273
页数:10
相关论文
共 105 条
[1]
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer [J].
Adelstein, Barbara-Ann ;
Dobbins, Timothy A. ;
Harris, Carole A. ;
Marschner, Ian C. ;
Ward, Robyn L. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (09) :1343-1354
[2]
Al-Mulla F, 1999, J PATHOL, V187, P433, DOI 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO
[3]
2-E
[4]
Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab forMetastatic Colorectal Cancer [J].
Aljehani, Mayada A. ;
Morgan, Johnw. ;
Guthrie, Laurel A. ;
Jabo, Brice ;
Ramadan, Majed ;
Bahjri, Khaled ;
Lum, Sharon S. ;
Selleck, Matthew ;
Reeves, Mark E. ;
Garberoglio, Carlos ;
Senthil, Maheswari .
JAMA SURGERY, 2018, 153 (01) :60-67
[5]
Amersi Farin, 2005, Clin Colon Rectal Surg, V18, P133, DOI 10.1055/s-2005-916274
[6]
Andre T, 2017, P AN M AM SOC CLIN, V35, P353
[7]
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[8]
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, JR ;
Clarke, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684
[9]
Effects of Activin and TGFβ on p21 in Colon Cancer [J].
Bauer, Jessica ;
Sporn, Judith C. ;
Cabral, Jennifer ;
Gomez, Jessica ;
Jung, Barbara .
PLOS ONE, 2012, 7 (06)
[10]
Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival [J].
Benedix, Frank ;
Kube, Rainer ;
Meyer, Frank ;
Schmidt, Uwe ;
Gastinger, Ingo ;
Lippert, Hans .
DISEASES OF THE COLON & RECTUM, 2010, 53 (01) :57-64